Page last updated: 2024-12-11
phenylahistin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
phenylahistin: antineoplastic from Aspergillus ustus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9798496 |
CHEMBL ID | 319291 |
SCHEMBL ID | 81222 |
MeSH ID | M0305583 |
Synonyms (9)
Synonym |
---|
(-)-phenylahistin |
CHEMBL319291 |
phenylahistin |
SCHEMBL81222 |
200815-37-8 |
(3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione |
GWMHBVLPNWHWGW-CNYBTUBUSA-N |
Q15425275 |
DTXSID801336373 |
Research Excerpts
Overview
Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. It is a new cell cycle inhibitor produced by Aspergillus ustus.
Excerpt | Reference | Relevance |
---|---|---|
"Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. " | ( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity. Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008) | 2.15 |
"Phenylahistin is a new cell cycle inhibitor produced by Aspergillus ustus. " | ( Antitumor activity of phenylahistin in vitro and in vivo. Hayashi, Y; Kanoh, K; Katada, J; Kohno, S; Muramatsu, M; Uno, I, 1999) | 2.06 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" (-)-Phenylahistin proved to be less toxic on P450-rich hepatocytes than on P450-deprived KB lines." | ( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity. Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008) | 1.22 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1587854 | Antiproliferative activity against human MCF cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID1587851 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID1587856 | Antiproliferative activity against mouse P388 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID1587853 | Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID1587852 | Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID1587855 | Antiproliferative activity against human WiDr cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
AID628581 | Cytotoxicity against human HT-29 cells | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants. |
AID1587850 | Antiproliferative activity against human A432 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.47) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (27.27%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (72.73%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |